Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus camrelizumab and apatinib conversion therapy for unresectable hepatocellular carcinoma with portal vein tumor thrombus
ChiCTR2500099280Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, Rivoceranib and durvalumab + lenvatinib + gemcitabine + cisplatin in hepatocellular carcinoma (HCC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Objective response rate, Surgical conversion rate and 1 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranibdurvalumab + lenvatinib + gemcitabine + cisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500099280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099280.